November 4, 2025 — Coya Therapeutics, Inc. (NASDAQ: COYA) announced positive results from an in vivo animal study evaluating COYA 303, a biologic combination, in a mouse model of systemic and neurologic inflammation.
The study confirmed interim findings that COYA 303 modulates immune parameters and shifts monocytes from a pro-inflammatory to an anti-inflammatory phenotype, enhancing Treg stability and suppressive capacity.
Coya intends to publish the full dataset. The company believes COYA 303 has significant effects on multiple Treg-associated activation and functional markers. Dr. Fred Grossman, Coya’s Chief Medical Officer, stated the study strengthens the company’s approach to developing new therapies for unmet medical needs. Dr. Arun Swaminathan, Coya’s CEO, believes the data supports COYA-303’s potential to improve the efficacy of GLP-1 RA in neurodegenerative diseases like Alzheimer’s Disease synergistically.
The anticipated readout of the Novo Nordisk EVOKE and EVOKE+ trials studying semaglutide, a GLP-1 RA in patients with mild Alzheimer’s Disease will inform Coya’s strategy moving forward.
Dr. Fred Grossman, Coya’s Chief Medical Officer
Dr. Arun Swaminathan, Coya’s CEO
Source: Coya Therapeutics, Inc.
